# Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

> **NCT05398848** · PHASE3 · COMPLETED · sponsor: **Jiangsu Rec-Biotechnology Co., Ltd.** · enrollment: 7623 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant two-component COVID-19 vaccine (CHO cell)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05398848
- **Lead sponsor:** Jiangsu Rec-Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-31
- **Primary completion:** 2023-09-04
- **Final completion:** 2023-12-29
- **Target enrollment:** 7623 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05398848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05398848, "Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05398848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*